Enhertu recommended for approval in the EU by CHMP as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer Based on DESTINY-Breast05 ...
A B.C. man who developed severe health complications after receiving the AstraZeneca COVID-19 vaccine has launched a lawsuit against the pharmaceutical company, the federal and provincial governments, ...
Enhertu recommended for approval in the EU by CHMP as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer Based on DESTINY-Breast05 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results